Proven survival in a randomized Phase III clinical trial
The National Cancer Institute of Canada evaluated Tarceva in a trial of second- and third-line patients with Stage IIIB or IV NSCLC. This double-blind, placebo-controlled Phase III study assessed Tarceva 150 mg monotherapy versus placebo in a randomized 2:1 design in a well-balanced patient population in which no preselection of patients was done to enrich the study.
Important dosing information
The recommended daily dose of Tarceva for NSCLC is 150 mg. Tarceva is available in three strengths—150 mg, 100 mg and 25 mg—to allow for dose reduction if necessary, and should not be taken with food
Tarceva.com
This site is only intended for use by healthcare professionals outside of the US. If you are a US resident, please visit www.tarceva.com.
ECCO 15 ESMO 34, Berlin, 2009
Watch Dr Schumann speaking about results from a study of erlotinib in advanced non-small-cell lung cancer (NSCLC), ECCO 15 ESMO 34, Berlin, 2009
- Disclaimer: Tarceva.net is a compreshesive resource for healthcare professionals outside the US. If you are a US resident please visit www.Tarceva.com. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.
- © 2010 F. Hoffmann-La Roche Ltd.